APA (7th ed.) Citation

HJ, J., G, H., AW, M., Z, M., EA, R., T, H., . . . ER, P. (2023). A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(11), 2052. https://doi.org/10.1158/1078-0432.CCR-22-3642

Chicago Style (17th ed.) Citation

HJ, Jang, et al. "A Phase II Trial of Guadecitabine Plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing After Initial Immune Checkpoint Inhibitor Therapy." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 29, no. 11 (2023): 2052. https://doi.org/10.1158/1078-0432.CCR-22-3642.

MLA (9th ed.) Citation

HJ, Jang, et al. "A Phase II Trial of Guadecitabine Plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing After Initial Immune Checkpoint Inhibitor Therapy." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 29, no. 11, 2023, p. 2052, https://doi.org/10.1158/1078-0432.CCR-22-3642.